Teva Pharmaceutical Industries Ltd (NYSE:TEVA) was
upgraded by equities research analysts at HSBC from a “hold” rating to a “buy”
rating in a research report issued to clients and investors on Monday.
Other analysts have also issued research reports about the
company. Morgan Stanley reaffirmed an “overweight” rating and set a $69.00
price objective (down previously from $71.00) on shares of Teva Pharmaceutical
Industries in a research report on Tuesday, May 3rd. Mizuho reaffirmed a “buy”
rating and set a $75.00 price objective (down previously from $78.00) on shares
of Teva Pharmaceutical Industries in a research report on Sunday, May 8th.
Zacks Investment Research raised Teva Pharmaceutical Industries from a “sell”
rating to a “hold” rating in a research report on Wednesday, June 15th. Goldman
Sachs Group Inc. lowered Teva Pharmaceutical Industries from a “buy” rating to
a “neutral” rating in a research report on Friday. Finally, Citigroup Inc.
reaffirmed a “buy” rating and set a $75.00 price objective on shares of Teva
Pharmaceutical Industries in a research report on Thursday, April 21st. One
analyst has rated the stock with a sell rating, five have issued a hold rating,
twenty have assigned a buy rating and one has given a strong buy rating to the
company’s stock. The stock presently has a consensus rating of “Buy” and a
consensus price target of $70.35.
Source: American Banking and Market News